News blog

FDA advisors vote against new diabetes drug

A US Food and Drug Administration (FDA) advisory committee has recommended against the approval of dapagliflozin, a diabetes drug that acts by increasing the body’s excretion of sugar.

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE